About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site   |  How to Help!

Patients Against Lymphoma

 

Clinical Trials > By Treatment OR Target type

Last update: 12/08/2011

TREATMENT OR TARGET TYPE

  Antiangiogenesis | anti-Apoptosis inhibitors | Antibodies | Antibodies & Biologics without chemoAntisense (anti-bcl-2) | Arsenic Trioxide | Bexxar | BendamustineBMS-247550Bryostatin | Chemotherapy | Enzastaurin | Enzyme inhibiting | GvHD | HDAC inhibitors | Immune-based | Liposomal Agents | mTOR | ONTAK | Pixantrone | Radiotherapy | RadioimmunotherapyRevlimid (Lenalidomide) | SAHA SGN-30 Stem Cell transplants | Targeted Agents | Vaccines | Velcade - proteasome inhibitor | Zevalin | Other 

See also
Pipeline | New Trials | 7 Reasons to Consider Trials: based on clinical circumstance
   NEW Find Trials by Type of Lymphoma & Treatment Status
NEW Find Trials by Agent / Protocol type

 Anti-angiogenesis

Return to top

Antiangiogenesis agents for lymphoma
bullet
All studies  
 
The goal is to target the blood supply that feeds tumors.
 
bullet
More agents of this type...

 Antibodies
(monoclonal) 

with or without chemotherapy

Also see Targeted 
agents
below

 

Return to top


 Antibodies (monoclonal) with or without chemotherapy

Targeted agents that bind to receptors on tumor cells.

bullet
Antibodies (monoclonal) with or without chemotherapy studies

Targets a specific receptor type on the surface of malignant cells 
bullet
HuMax-cd20 studies 

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

bullet
Rituxan studies (Rituximab)

TOPIC SEARCH: Mechanisms PubMed 

 

bullet
Bispecific antibody studies
Targets two receptor types on the malignant cells with one antibody

TOPIC SEARCH: Mechanisms PubMed 

 

Antibodies & Biologics

excluding chemotherapy

Also see Targeted 
agents
below

 

Return to top

 


Antibodies (monoclonal) excluding chemotherapy

bullet
studies excluding chemo ...  for previously untreated patients
bullet
studies excluding chemo and radioimmunotherapy
bullet
studies excluding chemo, radioimmunotherapy and Rituxan
bullet
studies of next generation CD20 targeting, not Rituxan (edited Oct 2007)

NOTE:  Many next-generation anti-cd20 Mabs are emerging.

Biologics 

bullet
studies of Cytokines | Biological response modifiers

Antigen-specific antibodies:

bullet
Anti-Tac (for Tac-expressing lymphoma, including T-cell NHL)
bullet
Daclizumab (t-cell lymphomas)
bullet
CD22-targeting
bullet
Rituxan  (CD20 targeting)
ONTAK (Denileukin Diftitox)

Ontak is a fusion protein which adheres to the interleukin-2 receptor on the malignant cell which may cause cell death.

bullet
ONTAK studies

TOPIC SEARCH: Mechanisms PubMed 

 
SGN-30   

" is a monoclonal antibody that targets the CD30 antigen, which is expressed on hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Seattle Genetics is conducting ongoing phase II clinical trials of SGN-30 as a single agent in systemic ALCL and cutaneous ALCL." Press release

bullet
SGN-30 studies

TOPIC SEARCH: Mechanisms PubMed 
 

 

Antibodies combined with biologics: 

bullet
studies of IL-2IL-12 | CpG | Anti-cd80 antibody 
bullet
studies of Antisense | G-CSF (Neupogen)
bullet
NEW: studies of GM-CSF (Leukine) 

TOPIC SEARCH: GM-CSF mechanisms with Rituxan PubMed 

  

Cytotoxic (chemo) agents 

And not Transplant
Also see Liposomal chemotherapy below.
 Related topics:

Chemotherapy

 
Return to top

 


Chemotherapy (general)

bullet
Chemotherapy-based studies: All phases | Phase I | Phase II | Phase III  

Chemotherapy is a general term for a systemic therapy. 

Click here for details on meaning of Phase I, II, III studies.
bullet
Chemotherapy with biologics studies 
bullet
High Dose Cytoxan and biologics studies (by request) 

Arsenic Trioxide

Arsenic trioxide may induce cell death (apoptosis) and normalization (differentiation) thru novel pathway(s). Approved for leukemia.

Bendamustine 

Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazol group.  It has shown activity against refractory lymphomas - lymphomas resistant to treatment.

Related articles BMR effective - ASH 2006  B + R - ASH 2006
bullet
Bendamustine studies 

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

 

BMS-247550

bullet
BMS-247550 studies 
 
Epothilone B-Analog. Primarily for relapsed aggressive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 

 

Bryostatin 

Possible mechanism of action: "Bryostatin-1 is believed to bind to the regulatory domain of the PKC enzyme suggesting a mechanism of action distinct from other kinase modulators in development." - gpc-ag.com

bullet
Bryostatin studies 
 

TOPIC SEARCH: Mechanisms PubMed 

  

 

Pixantrone

Might have similar activity against aggressive lymphomas as doxorubicin, with less cardio toxicity.  prnews 

 Related Abstracts:  Pixantrone 
bullet
Pixantrone studies 
 

Graft vs Host Disease

 Related Abstracts:

Graft vs Host | Novel
 
Return to top

Graft vs Host Disease studies
bullet
All studies 
studies for acute GvHD  | chronic GvHD  
 
Graft vs. Host Disease (GvHD) -  a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GvHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants.  See GvHD for more detail.

TIP: After you click the query above, click
Results on Ma
p tab to find locations of the studies in your region.

 

Immunotherapy

Also see Antibodies and Radioimmunotherapy and  Vaccine  
 Related Abstracts:

general

 vaccines

 
Return to top
 

Immune-based studies
bullet
Immunotherapy without chemo or radiotherapy
| phase I for this type
bullet
CTLA4 
bullet
EBV-specific lymphocyte therapy
bullet
Peripheral blood lymphocyte therapy 
bullet
Immune-modulator therapy without chemotherapy
 
The goal of this investigative treatment type is to modify the immune system in order to fight lymphoma or enhance other treatments.


Lenalidomide (CC-5013, Revlimid) 
 
Immune modulation (IMiD) 

"Lenalidomide...  may decrease the production of cytokine and growth factors decreasing the growth of the cells or new blood vessels for the cells. ...  it could also improve the function of natural killer T cells, and enhance immunity.

Lenalidomide is currently approved by the FDA for the treatment of multiple myeloma, another type of cancer that affects circulating plasma cells, which produce antibodies. Lenalidomide is currently awaiting FDA approval for CLL and NHL."

bullet
Revlimid (Lenalidomide) studies 

Mechanisms PubMed 
 

 

Gallium Nitrate
Ganite

Return to top

 
bullet
Gallium Nitrate studies
 
The goal is induce lymphoma cell death, selectively.  Trials appear to be closed as of 11/2005.  Outcome data has not been presented yet.

Liposomal 
Delivery of Drugs

Related Abstracts:

liposomal doxorubicin 
 
liposomal vincristine 
 
liposomal antisense

Topics:

 Liposomal chemo
Return to top

 


Liposomal Delivery of Drugs

bullet
Liposomal versions of biologics and chemotherapy
 
Liposomal delivery of treatments may reduce side effects and/or improve efficacy.

Radiotherapy 

 Related Abstracts:

  radiotherapy
 
Return to top

 


Radiotherapy 

bullet
Radiotherapy all stages - Stage I | Stage II | Stage III | Stage IV
bullet
Excluding chemotherapy

 

Radioimmuno-
therapy

Zevalin 
(Y 90 Ibritumomab Tiuxetan)
and 
Bexxar 
(iodine I 131 tositumomab)
 Related Abstracts:

  Radioimmunotherapy

 
Return to top

 


Radioimmunotherapy (general)

bullet
All lymphoma studies utilizing radioimmunotherapy (RIT)
bullet
  RIT studies in Canada (by request)
bullet
RIT for untreated lymphoma
bullet
RIT as part of Stem Cell Transplant (bitly)
bullet
RIT-based sequential therapy 

Sequential therapy is following one treatment with another in order to improve on the response of the first.  Also called Consolidation therapy.
bullet
BexxarZevalin  (two approved kinds of RIT)  
bullet
See Comparing Bexxar and Zevalin 
bullet
DLBCL and Radioimmunotherapy
bullet
High dose, or maximum tolerated doses of treatment with RIT
 

Bexxar (approved)

bullet
Bexxar (Tositumomab, Iodine I 131)
 
Radioimmunotherapy for CD20 positive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 

Also see Radiolabeled Antibodies
 

Zevalin (approved) (90Y - Ibritumomab tiuxetan)

bullet
Zevalin
 
Radioimmunotherapy for cd20 positive lymphomas

TOPIC SEARCH Zevalin: Mechanisms PubMed 

Also see Radio-labeled Antibodies

TIP: After you click the query above, click
Results on Ma
p tab to find locations of the studies in your region.

Stem Cell Transplants 

 Related  Abstracts:

 General - all

Allogeneic (from donor) 

Non-ablative (mini)

 Autologous (self)
 
Return to top

 


Stem Cell Transplants for Lymphoma / CLL

bullet
All transplant studies
bullet
Autologous (from self) *
bullet
Studies exploring alternative mobilization strategies
bullet
Allogeneic types (from donor) *
bullet
Mini - nonmyeloablative transplants for NHL  *
bullet TIP: After you click the query above, click
Results on Ma
p tab to find locations of the studies in your region.
Nonmyeloablative therapy is sometimes called a mini transplant, adoptive immunotherapy, or non-ablative transplant. 
 
With this treatment relatively low dose of chemotherapy are used to suppress the patient's immune system enough to prevent rejection of the donor cells and control the lymphoma. The pre-transplant regimen (chemo) must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the Graft vs. Tumor (GVT) effect to occur -- which relies on the killing action of the donor’s immune cells to eradicate the remaining disease. 

  Targeted agents

Also see antibodies above
Also see Pipeline
 
Return to top

 

 


Targeted agents

Targeted therapy is a type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with rapidly dividing cells. Targeted cancer therapies may be more effective than current treatments and less harmful to normal cells.    The main categories of targeted therapy are small molecules and monoclonal antibodies.  Source: Wikipedia.org


anti-apoptosis inhibitors 

Agents that target pathways in malignant cells that resist apoptosis
bullet
anti-apoptosis inhibitors studies: 
 
ABT-263  | APO866 | AT-101 | GMX1777 | GX15-070 | YM155

 
Antisense (anti-bcl-2) (Oblimersen sodium, Genasense)

Antisense therapy inhibits cell production of bcl-2, a protein that is thought to inhibit cell death and increase resistance to cancer therapies.  Thus, the goal of antisense therapy is to sensitize cancer cells to cancer treatments. It may also have activity as a single agent.

bullet
Antisense (anti-bcl-2) studies  

TOPIC SEARCH: Mechanisms PubMed 

 

 
Enzyme inhibiting therapies  

Related topics: Enzyme therapy 
Related Abstracts: proteasome inhibitors
bullet
Enzyme Inhibiting studies 
bullet
Velcade  (PS-341/ Bortezomib) proteasome inhibitor
bullet
Bortezomib for NHL (Velcade / PS-341)  
 
(Recently approved for Multiple Myeloma and Mantle Cell Lymphoma.)

The goal of this investigative treatment type is to inhibit the breakdown of proteins in the malignant cells, which produce and require the elimination of more proteins than normal cells.
bullet
Also see Studies for Enzyme inhibitor Therapies for lymphoma


Histone deacetylase (HDAC) inhibitor  

Related Abstracts: HDAC
bullet
HDAC inhibitors studies
 
"HDAC inhibitor MS-275, a benzamide derivative, has demonstrated potent and unique cytotoxicity and anticancer activity in vitro (test tube) in human tumor cell lines and, more importantly, in vivo in human tumor xenografts." 
bullet
SAHA   (suberoylanilide hydroxamic acid) (Vorinostat) 
bullet
Vorinostat  studies

TOPIC SEARCH: Mechanisms PubMed 

Kinase inhibitors 

bullet
all kinase inhibitors studies
bullet
tyrosine kinase inhibitor studies
Enzastaurin  (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme.
bullet
Enzastaurin studies

 
mTOR inhibitors
 

"In many cancers, mTOR is inappropriately “switched on” due to the abnormal activation of one or more of the upstream signaling pathways that regulate mTOR activity. As a result, mTOR’s ability to inhibit protein synthesis and cause growth arrest when nutrients are scarce becomes compromised."  Background from a sponsor: http://www.targetmtor.com 

bullet
mTOR inhibitors for all lymphomas
 

 

   Vaccines

 Related Abstracts:

general 

Idiotype-specific 
 

Return to top

 

 


Vaccines

bullet
Vaccines (Therapeutic)  for Lymphoma  
bullet
for CLL
bullet
for follicular Lymphoma 
bullet
Produced by tobacco plant
bullet
for Mantle Cell Lymphoma
The goal of this investigative treatment is to educate the immune system to identify and target proteins found only on tumors.

  Other New Agents

 Related Abstracts:

Paclitaxel 

SB-715992 - ASCO

Also see Pipeline
 

Return to top

 

 


Other New agents

bullet
CDDO  

"CDDO is a novel synthetic triterpenoid which is a potent multifunctional molecule. It induces apoptosis in vitro in malignant cells through both intrinsic and extrinsic pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by serving as a ligand for the transcription factor peroxisome proliferator activator receptor- gamma (PPAR gamma ). " Related articles
bullet
SB-715992  
 
"The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle. KSP represents a novel target for development of therapeutics against cancer. SB-715992 is a unique and selective inhibitor of KSP, that is preferentially overexpressed in malignant cells, functions exclusively in mitosis, and is not expressed in terminally differentiated neurons." - ASCO | Safety reports
bullet
Elsamitrucin 
bullet
Paclitaxel
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.